Jane Street
ORIC icon

Jane Street’s Oric Pharmaceuticals ORIC Stock Holding History

Jane Street’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,000
Closed -$156K – 12025
2025
Q3 		$156K Buy
+13,000
New +$137K ﹤0.01% 9857
2025
Q1 		– Sell
-20,000
Closed -$161K – 10289
2024
Q4 		$161K Buy
+20,000
New +$184K ﹤0.01% 8545

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street's ORIC Position: Q2 2026 in Review

Jane Street sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 53,037 shares — an estimated $672K sold.

Jane Street first reported a position in ORIC in Q2 2020 and held it in 12 quarters. The position peaked at $2M in Q4 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Jane Street reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 53,037 Oric Pharmaceuticals shares in Q2 2026, an estimated $672K.
  • Jane Street first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 12 quarters.
  • Jane Street's Oric Pharmaceuticals position peaked at $2M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.